Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Gossamer Bio Inc
GOSS
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$9.58
1.15
13.64%
Dern. MÀJ: Oct 20, 7:13 PM
$9.44
1.01
11.98%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Gossamer Bio Financials
Gossamer Bio (GOSS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 52.94 percent increase over losses of $(0.17) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q1 EPS $(0.20) Misses $(0.13) Estimate, Sales $16.955M Beat $4.475M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.13) by 53.85 percent. This is a 25 percent decrease over losses of $(0.16) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q4 EPS $(0.21) Misses $(0.18) Estimate, Sales $13.799M Beat $7.522M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 14.13 percent. This is a 40 percent decrease over losses of $(0.15) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $13.294M
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 16.02 percent. This is a 50 percent decrease over losses of $(0.14) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q2 EPS $(0.17) Beats $(0.18) Estimate, Sales $11.49M Beat $4.34M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.03 percent. This is a 177.27 percent decrease over earnings of $0.22 per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q1 EPS $(0.16) Beats $(0.18) Estimate, Sales $9.89M Beat $4.07M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 15.79 percent increase over losses of $(0.19) per share from the
Benzinga Newsdesk
